COOK IRELAND LTD ZILVER PTX 35 DRUG-ELUTING STENT; NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
|
Back to Search Results |
|
Catalog Number UNKNOWN |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Stenosis (2263); Restenosis (4576)
|
Event Date 07/01/2019 |
Event Type
Injury
|
Manufacturer Narrative
|
Investigation is still pending, a follow up mdr will be submitted to include the investigation conclusions.
|
|
Event Description
|
Ichihashi et al 2019 (zilver ptx) ¿ ¿vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after zilver ptx paclitaxel-coated stent placement¿.The selection of guidewires, subintimal/intraluminal passage, and sizes of balloons and stents were at the opera-tor¿s discretion.After 6-f sheath insertion, unfractionated heparin (5000 units) was administered.Intravascular ultrasound (ivus) was used at the operator¿s discretion to assess vessel diameter for balloon and stent selection.Stenting with zilver ptx was performed successfully in every limb without significant residual stenosis.Stented length was 16.2±9.3 cm (range 4¿40).Forty lesions were recanalized via a total or partial subintimal passage.Clinically-driven tlr was defined as a secondary procedure performed for =50% diameter stenosis within ±5 mm of the target lesion after recurrent clinical symptoms of pad.54 tlrs were subsequently performed.The 1-, 2-, and 5-year kaplan-meier estimates of primary patency and freedom from clinically-driven tlr were 76.0%, 63.7%, and 45.0% and 84.7%, 73.7%, and 54.2%, respectively.
|
|
Manufacturer Narrative
|
Device evaluation: the zisv6 devices of unknown lot number involved in this complaint were implanted in the patients and were not available for evaluation.With the information provided, a document based investigation was conducted.Document review: as the rpn and lot number of the complaint stents are unknown, a review of the relevant manufacturing records cannot be conducted.However, prior to distribution zisv6 devices are subjected to a visual inspection and functional checks to ensure device integrity.These inspections and functional checks are outlined in internal procedures in place at cirl: it should be noted that restenosis of the stented artery is listed as a known potential adverse event within the instructions for use (ifu0117-5).There is no evidence to suggest the user did not follow the ifu.Root cause review: a definitive root cause could not be determined from the available information.A possible root cause could be attributed to patient pre-existing/underlying conditions.From the literature article it is known that patient pre-existing conditions included hypertension, hyperlipidaemia, diabetes, smoking, coronary artery disease (cad), renal insufficiency, critical limb ischemia and rutherford classifications between 2 and 5.Restenosis of the stented artery is also listed as a known potential adverse event within the ifu and is a common adverse event of endovascular procedures that can be caused by injury to the vessel (e.G.During percutaneous transluminal angioplasty (pta) and/or stenting).Vessel injury provokes an inflammatory response that leads to or amplifies the restenosis process.It may be noted that the surface of the zilver ptx stent is coated with the drug paclitaxel to help prevent subsequent restenosis of the artery.Summary: complaint is confirmed based on customer testimony.The patient outcome is unknown.Complaints of this nature will continue to be monitored for potential emerging trends.
|
|
Event Description
|
Supplemental report is being submitted due to the completion of the investigation.
|
|
Search Alerts/Recalls
|
|
|